Investigating cancer incidence in Parkinson's patients with a specific gene mutation
Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene
This study looks at whether people with Parkinson's disease who have a specific gene mutation are more likely to develop cancer compared to those without the mutation and the general population.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda USL Reggio Emilia - IRCCS Government |
| Locations | 4 sites (Brindisi and 3 other locations) |
| Trial ID | NCT06814431 on ClinicalTrials.gov |
What this trial studies
This multicenter retrospective observational study examines the incidence of malignant neoplasms in patients with Parkinson's disease (PD) who carry heterozygous mutations in the GBA1 gene. It compares these patients to those with idiopathic PD and the general population using data from local cancer registries. The study aims to determine if there is a higher incidence of cancer among GBA1 mutation carriers and to characterize the types of cancers present. Approximately 3000 PD patients will be included, with a focus on understanding the relationship between genetic factors and cancer risk.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with Parkinson's disease, particularly those with GBA1 mutations.
Not a fit: Patients with uncertain diagnoses of Parkinson's disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the cancer risks associated with genetic mutations in Parkinson's disease, potentially leading to improved monitoring and treatment strategies.
How similar studies have performed: While there is growing evidence of increased cancer risk in patients with Gaucher disease, this specific investigation into GBA1 mutations in Parkinson's disease is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years * Diagnosis of Parkinson's Disease through the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's Disease. Exclusion Criteria: * Uncertain diagnosis
Where this trial is running
Brindisi and 3 other locations
- Ospedale A. Perrino — Brindisi, Italy (Recruiting)
- IRCCS Istituto Neurologico Carlo Besta — Milan, Italy (Recruiting)
- Azienda USL IRCCS di Reggio Emilia — Reggio Emilia, Italy (Recruiting)
- Ospedale Santa Chiara di Trento — Trento, Italy (Recruiting)
Study contacts
- Study coordinator: Franco Valzania, MD
- Email: franco.valzania@ausl.re.it
- Phone: +39 0522 296494
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.